Prevents organ rejection. ANDA 212130, held by Meitheal. Mycophenolate Mofetil Hydrochloride.
As of Nov 16, 2026, ANDA 212130 (Mycophenolate Mofetil Hydrochloride), held by Meitheal, was first approved by FDA on Jan 15, 2021, with 6 approved supplements and 0 published complete response letters.
Mycophenolate Mofetil is indicated for the prophylaxis of organ rejection, in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants. Mycophenolate Mofetil is an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 15, 2021 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Mycophenolate Mofetil Hydrochloride500MG/VIAL · injectable;injection | Mycophenolate Mofetil Hydrochloride | Rx |
| Jul 29, 2026 | Supplement 16REMS | Approved | None posted |
| Aug 13, 2024 | Supplement 10REMS | Approved | None posted |
| Jun 22, 2023 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jun 22, 2023 | Supplement 5Labeling · Standard review | Approved | None posted |
| Aug 11, 2021 | Supplement 3REMS | Approved | None posted |
| Apr 21, 2021 | Supplement 2REMS | Approved | None posted |
| Jan 15, 2021 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters